Nonmelanoma Skin Cancer of the Head and Neck: Nonsurgical Treatment

Facial Plastic Surgery Clinics of North America

Volumn 20, Issue 4, 2012, Pages 445-454

  Ermertcan, Aylin Türel ^a   Hellings, Peter W ^b   Cingi, Cemal ^c  

^a CELAL BAYAR UNIVERSITY   (Turkey)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

Nonmelanoma; Nonsurgical; Skin cancer; Treatment

Indexed keywords

AFAMELANOTIDE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; AMINOLEVULINIC ACID; BETULIC ACID; BETULIN; CAPECITABINE; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; IMIQUIMOD; INTERFERON; ISOTRETINOIN; LUPEOL; OLEANOLIC ACID; PANITUMUMAB; PHOTOFRIN; PROTOPORPHYRIN; RESIQUIMOD; RETINOIC ACID; RETINOID; TAZAROTENE; UNINDEXED DRUG; VERTEPORFIN; VISMODEGIB;

ACTINIC KERATOSIS; BASAL CELL CARCINOMA; CANCER MORTALITY; CANCER RADIOTHERAPY; CARBON DIOXIDE LASER; CONSERVATIVE TREATMENT; CRYOTHERAPY; CURETTAGE; DESICCATION; DISEASE SEVERITY; ELECTRODESICCATION; EXTERNAL BEAM RADIOTHERAPY; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LASER; MORBIDITY; NEODYMIUM LASER; NEODYMIUM YAG LASER; NONHUMAN; NONMELANOMA SKIN CANCER; PHOTODYNAMIC THERAPY; REVIEW; RISK FACTOR; SKIN CANCER; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

AGE FACTORS; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CICATRIX; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM INVASIVENESS; RISK FACTORS; SKIN NEOPLASMS;

EID: 84867770220     PISSN: 10647406     EISSN: 15581926     Source Type: Journal    
DOI: 10.1016/j.fsc.2012.08.004     Document Type: Review

References (61)

1. Gaspari A.A., Sauder D.N. Immunotherapy of basal cell carcinoma: evolving approaches. Dermatol Surg 2003, 29(10):1027-1034.
2. Chakrabarty A., Geisse J.K. Medical therapies for nonmelanoma skin cancer. Clin Dermatol 2004, 22:183-188.
3. Nyugen T.H., Ho D.Q. Nonmelanoma skin cancer. Curr Treat Options Oncol 2002, 3:193-203.
4. Amini S., Viera M.H., Valins W., et al. Nonsurgical innovations in the treatment of nonmelanoma skin cancer. J Clin Aesthet Dermatol 2010, 3:20-34.
5. McGuire J.F., Ge N.N., Dyson S. Nonmelanoma skin cancer of the head and neck I: histopathology and clinical behavior. Am J Otolaryngol 2009, 30(2):121-133.
6. Seidler A.M., Bramlette T.B., Washington C.V., et al. Mohs versus traditional surgical excision for facial and auricular nonmelanoma skin cancer: an analysis of cost-effectiveness. Dermatol Surg 2009, 35(11):1776-1787.
7. Bagheri M., Safai B. Cutaneous malignancies of keratinocytic origin. Clin Dermatol 2001, 19:244-252.
8. King S.C., Chen S. Analyzing the cost of preventing nonmelanoma skin cancer. J Invest Dermatol 2009, 129(12):2745-2746.
9. Gibbs P., Gonzalez R., Lee L., et al. Medical management of cutaneous malignancies. Clin Dermatol 2001, 19:298-304.
10. Ho T., Byrne P.J. Evaluation and initial management of the patient with facial skin cancer. Facial Plast Surg Clin North Am 2009, 17(3):301-307.
11. Ge N.N., McGuire J.F., Dyson S., et al. Nonmelanoma skin cancer of the head and neck II: surgical treatment and reconstruction. Am J Otolaryngol 2009, 30(3):181-192.
12. Lien M.H., Sondak V.K. Nonsurgical treatment options for basal cell carcinoma. J Skin Cancer 2011, 2011:571734. [Epub 2011 Jan 9].
13. Kim K.H., Yavel R.M., Gross V.L., et al. Intralesional interferon α-2b in the treatment of basal cell carcinoma and squamous cell carcinoma: revisited. Dermatol Surg 2004, 30:116-120.
14. Bonerandi J.J., Beauvillain C., Caquant L., et al. Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions. J Eur Acad Dermatol Venereol 2011, 25(Suppl 5):1-51.
15. Galiczynski E.M., Vidimos A.T. Nonsurgical treatment of nonmelanoma skin cancer. Dermatol Clin 2011, 29:297-309.
16. Robinson J.K. Advances in the treatment of nonmelanoma skin cancer. Dermatol Clin 1991, 9(4):757-764.
17. Rompel R. Dermatological surgery. Braun-Falco's dermatology 2009, 1613-1642. Springer Medizin Verlag Heidelberg, Italy. 3rd edition. W.H. Burgdorf, G. Plewig, M. Landthaler (Eds.).
18. Quinn A.G., Perkins W. Non-melanoma skin cancer and other epidermal skin tumours. Rook's textbook of dermatology 2010, vol. 52:1-48. Blackwell Science, Oxford (United Kingdom). 8th edition.
19. Lawrence C.M., Telfer N.R. Dermatological surgery. Rook's textbook of dermatology 2010, vol. 77:1-50. Blackwell Science, Oxford (United Kingdom). 8th edition.
20. Kuflik E.G., Gage A.A. The 5 year cure rate achieved by cryosurgery for skin cancer. J Am Acad Dermatol 1991, 24:1002-1004.
21. Holt P.J. Cryotherapy for skin cancer: results over a 5 year period using liquid nitrogen spray cryosurgery. Br J Dermatol 1998, 119:231-240.
22. Nordic P. Curettage-cryosurgery for nonmelanoma skin cancer of the external ear: excellent 5-year results. Br J Dermatol 1999, 140:291-293.
23. Kuflik E.G. Cryosurgery. Dermatology 2008, 2121-2126. Elsevier Ltd, St. Louis. 2nd edition. J.L. Bolognia, J.L. Jorizzo, R.P. Papini (Eds.).
24. Zacarian S.A. Cryosurgery of cutaneous carcinomas: an 18-year study of 3022 patients with 4228 carcinomas. J Am Acad Dermatol 1983, 9:947-956.
25. Odom R.B., James W.D., Berger T.G. Dermatologic surgery. Andrews' diseases of the skin 2000, 1073-1090. WB Saunders Co, Philadelphia. 9th edition.
26. Odom R.B., James W.D., Berger T.G. Epidermal nevi, neoplasms, and cysts. Andrews' diseases of the skin 2000, 800-868. WB Saunders Co, Philadelphia. 9th edition.
27. Spiller W.F., Spiller R.F. Treatment of basal cell epithelioma by curettage and electrodessication. J Am Acad Dermatol 1984, 11:808-814.
28. Ponten F., Lundeberg J., Asplund A. Principles of tumor biology and pathogenesis of BCCs and SCCs. Dermatology 2008, 1627-1659. Elsevier Ltd, St. Louis. 2nd edition. J.L. Bolognia, J.L. Jorizzo, R.P. Papini (Eds.).
29. Tope W.D., Bhardwaj S.S. Photodynamic therapy. Dermatology 2008, 2071-2087. Elsevier Ltd, St. Louis. 2nd edition. J.L. Bolognia, J.L. Jorizzo, R.P. Papini (Eds.).
30. Oseroff A. PDT as a cytotoxic agent and biological response modifier: implications for cancer prevention and treatment in immunosuppressed and immunocompetent patients. J Invest Dermatol 2006, 126:542-544.
31. Fritsch C., Goerz G., Ruzicka T. Photodynamic therapy in dermatology. Arch Dermatol 1998, 134:207-214.
32. Kalka K., Merk H., Mukhtar H. Photodynamic therapy in dermatology. J Am Acad Dermatol 2000, 42:389-413.
33. Soler A.M., Warloe T., Berner A., et al. A follow up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolevulinate-based photodynamic therapy alone and with prior curettage. Br J Dermatol 2001, 145:467-471.
34. Dilkes M.G., DeJode M.L., Rowntree-Taylor A., et al. m-THPC photodynamic therapy for head and neck cancer. Lasers Med Sci 1996, 11:23-29.
35. Rigel D.S., Cockerell C.J., Carucci J., et al. Actinic keratosis, basal cell carcinoma and squamous cell carcinoma. Dermatology 2008, 1641-1659. Elsevier Ltd, St. Louis. 2nd edition. J.L. Bolognia, J.L. Jorizzo, R.P. Papini (Eds.).
36. Non melanoma skin cancer: guidelines for treatment and management in Australia. Clinical practice guidelines 2002, National Health Medical Research Council, Canberra (Australia).
37. Clinical practice guidelines in oncology. Basal cell and squamous cell skin cancers. National Comprehensive Cancer Network. Available at: Accessed October 12, 2011. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
38. Kelly C.G., Peat I. Radiotherapy and reactions to ionizing radiation. Rook's textbook of dermatology 2010, vol. 79:1-19. Blackwell Science, Oxford (United Kingdom). 8th edition.
39. Hantash B.M., Stewart D.B., Cooper Z.A., et al. Facial resurfacing for non-melanoma skin cancer prophylaxis. Arch Dermatol 2006, 142:976-982.
40. Iyer S., Friedli A., Bowes L., et al. Full face laser resurfacing: therapy and prophylaxis for actinic keratoses and nonmelanoma skin cancer. Lasers Surg Med 2004, 34:114-119.
41. Moskalik K., Kozlov A., Demin E., et al. The efficacy of facial skin cancer treatment with high-energy pulsed neodymium and Nd: YAG lasers. Photomed Laser Surg 2009, 27:345-349.
42. Covadonga Martinez-Gonzalez M., del Pozo J., Paradela S., et al. Bowen's disease treated by carbon dioxide laser. A series of 44 patients. J Dermatolog Treat 2008, 19:293-299.
43. Epstein E. Fluorouracil paste treatment of thin basal cell carcinomas. Arch Dermatol 1985, 121:207-213.
44. Bargman H., Hochman J. Topical treatment of Bowen's disease with 5-fluorouracil. J Cutan Med Surg 2003, 7:101-105.
45. Cartei G., Cartei F., Interlandi G., et al. Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged. Am J Clin Oncol 2000, 23:181-184.
46. Geisse J., Caro I., Lindholm J., et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004, 50:722-733.
47. Beutner K.R., Geisse J.K., Helman D., et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999, 41:1002-1007.
48. Geisse J.K., Rich P., Pandya A., et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002, 47:390-398.
49. Jones T. Resiquimod 3M. Curr Opin Investig Drugs 2003, 4:214-218.
50. Niles R.M. The use of retinoids in the prevention and treatment of skin cancer. Expert Opin Pharmacother 2002, 3:299-303.
51. Peris K., Fargnoli M.C., Chimenti S. Preliminary observations on the use of topical tazarotene to treat basal cell carcinoma. N Engl J Med 1999, 341:1767-1768.
52. Alpsoy E., Yilmaz E., Basaran E., et al. Comparison of the effects of intralesional interferon alfa-2a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma. J Dermatol 1996, 23:394-396.
53. Cornell R.C., Greeenway H.T., Tucker S.B., et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol 1990, 23:694-700.
54. Stenquist B., Wennberg A.M., Gisslen H., et al. Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery. J Am Acad Dermatol 1992, 27:65-69.
55. Jager S., Laszczyk M.N., Scheffler A. A preliminary pharmacokinetic study of betulin, the main pentacyclic triterpene from extract of outer bark of birch (Betulae alba cortex). Molecules 2008, 13:3224-3235.
56. Krasutsky P.A. Birch bark research and development. Nat Prod Rep 2006, 23:919-942.
57. Huyke C., Reuter J., Rödig M., et al. Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study. J Dtsch Dermatol Ges 2009, 7:128-133.
58. Rudin C.M. Beyond the scalpel: targeting hedgehog in skin cancer prevention. Cancer Prev Res (Phila) 2010, 3:1-3.
59. Von Hoff D.D., LoRusso P.M., Rudin C.M., et al. Inhibition of the hedgehog pathway in advanced-basal cell carcinoma. N Engl J Med 2009, 361:1164-1172.
60. Bauman J.E., Eaton K.D., Martins R.G. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol 2007, 143:889-892.
61. Jirakulaporn T., Mathew J., Lindgren B.R., et al. Efficacy of capecitabine in secondary prevention of skin cancer in solid-organ transplanted recipients (OTR). J Clin Oncol 2009, 27:1519.